Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ...

Eligibility for treatment with the latest cancer drugs is often determined by genetic mutations in tumors, criteria that leave minority patients at a disadvantage due to their under-representation in ...

Research suggests the benefits of testosterone therapy after prostate cancer surgery in select men may outweigh risks.

Researchers at The Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of immunotherapy - ...